Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

NCT04971499 is registered in ClinicalTrials.gov with April Salama, M.D. as lead sponsor.

NCT NCT04971499
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04971499 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
Lead sponsor
April Salama, M.D.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 6, 2022
Completion date
April 30, 2027
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma